VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 124 filers reported holding VIRIDIAN THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,998,147 | +31.6% | 168,060 | +40.7% | 0.05% | +14.6% |
| Q1 2023 | $3,038,783 | -67.9% | 119,449 | -63.1% | 0.04% | -67.7% |
| Q4 2022 | $9,468,100 | +56.0% | 324,139 | +9.6% | 0.13% | +49.4% |
| Q3 2022 | $6,068,000 | -5.1% | 295,874 | -46.4% | 0.08% | -13.3% |
| Q2 2022 | $6,391,000 | +56.2% | 552,371 | +149.7% | 0.10% | +48.5% |
| Q1 2022 | $4,091,000 | -19.7% | 221,257 | -14.1% | 0.07% | -9.6% |
| Q4 2021 | $5,094,000 | – | 257,670 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,699,865 | $78,863,057 | 13.28% |
| COMMODORE CAPITAL LP | 2,020,166 | $59,009 | 8.89% |
| ACUTA CAPITAL PARTNERS, LLC | 396,500 | $11,581,765 | 7.13% |
| Fairmount Funds Management LLC | 1,369,623 | $40,006,688 | 6.35% |
| Paradigm Biocapital Advisors LP | 1,751,167 | $51,151,588 | 6.00% |
| Vivo Capital, LLC | 1,678,207 | $49,020 | 5.64% |
| TCG Crossover Management, LLC | 983,610 | $28,731,248 | 5.07% |
| Kynam Capital Management, LP | 1,034,697 | $30,223,499 | 4.64% |
| Octagon Capital Advisors LP | 824,200 | $24,074,882 | 3.75% |
| Logos Global Management LP | 1,000,000 | $29,210,000 | 3.42% |